Disturbed cerebral function in menopause and its prevention;Troubles de la fonction cerebrale au climatere et leur prophylaxie

Praxis

Volumn 86, Issue 36, 1997, Pages 1378-1382

  Altieri, M ^a   Bogousslavsky, J ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Alzheimer's disease; estrogen replacement therapy; estrogens; menopause; stroke

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ALZHEIMER DISEASE; BRAIN DYSFUNCTION; CEREBROVASCULAR ACCIDENT; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MENOPAUSE; ORAL DRUG ADMINISTRATION; REVIEW; STROKE; AGED; BRAIN; CEREBROVASCULAR DISEASE; CLIMACTERIUM; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; ALZHEIMER DISEASE; BRAIN; CEREBROVASCULAR DISORDERS; CLIMACTERIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED;

EID: 0030772623     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. La Vecchia C, Levi F.: Trends in cerebrovascular mortality in Western and Eastern Europe. Eur Neruol 1994; 24: 301-305.
2. Barnett H. J. M.: 35 years of stroke prevention: challenges, disappointments and success. Cerebrovasc dis 1991; 1: 61-70.
3. Bogousslavsky J., Van Melle G., Regli F.: The Lausanne stroke registry: analysis of 1000 consecutive patients with first stroke. Stroke 1988; 19: 1083-1092.
4. Wolf P. A., D'A gostino R. B., Belanger A. J., Kannel W. B.: Probability of stroke: a risk profile from the Framingham study. Stroke 1991; 22: 312-318.
5. Kurzke J. E: Epidemiology of cerebrovascular disease, in McDowell F. H., Caplan L. R. (eds): Cerebrovascular Survey Report. Dallas, American Heart Association 1985, pp1-34.
6. Longstreth W. T., Swanson P. D.: Oral contraceptives and stroke. Stroke 1984; 15: 747-750.
7. Paganini-Hill A., Ross R. K., Henderson B. E.: Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 1988:297519-522.
8. Henderson B. E., Paganini-Hill A., Ross R. K.: Decreased Mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75-78.
9. Falkeborn M., Persson I., Terent A., Adami H. O., Lithell H., Bergström R.: Hormone replacement therapy and the risk of stroke. Arch Intern Med 1993; 153: 1201-1209.
10. Gordon T., Kannel W. B., Hjortland M. C., McNamara P. M.: Menopause and coronary heart disease: The Framingham Study. Ann Intern Med 1978; 89: 157-161.
11. Kannel W. B., Hjortland M. C., McNamara P. M., Gordon T.: Menopause risk of cardiovascular disease: The Framingham Study. Ann Intern Med 1976; 85: 447-452.
12. Gangar K. F., Vyas S., Whitehead M., Crook D., Meire H., Campbell S.: Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991; 338: 839-842.
13. Scarabin P. Y., Bonithon-Kopp C. Bara L., Guize L., Samama S.: Relationship between plasminogen activator inhibitor activity and menopausal status. Fibrinolysis 1990: 4; 233-236.
14. Stampfer M. J., Colditz G. A., Willett W. C., Mansonje, Rosner B., Speizer F. E., Hennekens H.: Postmenopausal estrogen therapy and cardiovascular disease. N. Engl. J. Med. 1991: 325; 756-762.
15. Grodstein F., Stampfer M. J., Manson J. A. E., Colditz G. A., Willett W. C., Rosner B, Speizer F. E., Hennekens C. H.: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J. med 1996; 335: 453-461.
16. Boysen G., Nyboe J., Appleyard M., Sørensen P. S., Boas J., Somnier F., Jensen G., Schnohr P.: Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke 1988; 19: 1345-1353.
17. Hazzard W.: Estrogen replacement and cardiovascular disease: serum lipids and blood pressure effects. Ann Obstet Gynecol 1989; 161: 1847-1853.
18. Lamour Y.: Systèmes cholinergiques centraux et démences de type Alzheimer. In: Maladie de type Alzheimer et autres démences séniles. Fondation Nationale de Gérontologie 1984: 18-29.
19. Wilcock G. K., Esiri M. M., Bowen D. M. et al.: Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982: 57; 407-417.
20. Luine V. N., Park D., Joh T., Reis D., McEwen B. S.: Immunochemical demonstration of increased choline acetyltransferase concentration in rat preoptic area after estradiol administration. Brain Res 1980; 191: 273-277.
21. Luine V. N., McEwen B. S.: Sex differences in cholinergic enzymes of diagonal band nuclei in the rat preoptic area. Neuroendocrinology 1983; 36: 475-482.
22. Fillit H., Winreb H., Cholst I., Luine V., McEwen B., Amador K., Zobriskie J.: Observations in a preliminary open trials of estradiol therapy for senile dementia-Alzheimer's type. Psyehoneuroloendocrinology 1986; 11-337-345.
23. Tang M. X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H., Mayeux R.: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-432.
24. Henderson V. W., Paganini-Hill A., Emanuel C. K., Dunn M. E., Buckwalter J. G.: Estrogen repalcement therapy in older women: comparison between Alzheimer' desease cases and nondemented control subjects. Arch Neurol 1986; 19: 415-424.
25. Honjo H., Ogino Y., Naitoh K., Urabe M., Kitawaki J., Yaxuda J., Yamamoto T., Ishihara S., Okada H., Yonezawa T., Hayashi K., Nambara T.: In vivo effects by estrone sulfatate on the central nervous system-senile dementia (Alzheimer's type) J Steroid Biochem 1989; 34: 521-525.
26. Schneider L. S., Farlow M. R., Henderson V. W., Pogoda J. M.: Effects of estrogen replacement therapy on response to tacrine in patients with Alzneimer's disease. Neurology 1996; 46: 1580-1584.
27. Fernundo-Ruiz J. J., Amor J. C., Ramos J. A.: Time-dependent effects of estradiol and progesterone on the number of straital dopaminergic D2 receptors. Brain Res 1989; 476: 388-395.
28. Llau M. E., Nguyen L., Senard J. M., Rascal O., Montastruc J. L.,: Syndromes Parkinsoniens d'origine médicamenteuse: expérience d'un centre régional de pharmacovigilance sur dix ans. Rev Neurol 1994; 150 (11); 757-762.
29. Session D. R., Pearlstone M. M., Jewelewicz R., Kelly A. C: Estrogens and Parkinsons's disease. Medical Hyptoheses 1994; 42: 280-282.
30. Lopes P., Mensier A., Laurent F. X., Besse O.: Traitement hormonal substitutif de la ménopause et prévention des complications neurologiques. Contracept Fertil Sex 1995; 23 (5): 319-322.
31. Chiò A., Meinen P., Tribolo A., Schiffer D.: Risk factors in motor neuron disease: a case-control study. Neuroepidemiology 1991; 10: 174-184.
32. Levesque H., Cailleux N., Courtois H.: Hormonothérapie substitutive de la ménopause, hémostase et risque thromho-embolique. Journal des Maladies Vasculaires 1994; 19: 93-97.
33. Kuttenn F.: Schéma thérapeutique de la ménopause: les critères de choix. Rev Prat 1993; 43 (20): 2657-2664.
34. Nabulsi A. A., Folsom A. R., White A. et al.: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-1075.
35. Chetkowski R. J., Meldrum D. R., Steingold K. A. et al.: Biologic effects of transdermal estradiol. N Engl J Med 1986; 314: 1615-1620.
36. Notelovitz M., Kitchens C. S., Ware M. D., Hirchberg K., Coone L.: Combination estrogen and progestogen replacement therapy does not adversely affect coagulation. Obstet Gynecol 1983; 62: 596-600.
37. Mashchak C. A., Loba R. A.: Estrogen replacement therapy and hypertension. J Reprod Med 1985: 30: 805-810.
38. Lobo R. A.: Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 1995; 173: 982-990.
39. Elkind-Hirsch K. E., Sherman L. D., Malinuk R.: Hormon replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab 1993; 776-742-745.